• Midazolam hydrochloride is a water-soluble benzodiazepine available as a sterile, nonpyrogenic parenteral dosage form for intravenous or intramuscular injection. (nih.gov)
  • Midazolam should not be administered by rapid injection in the neonatal population. (nih.gov)
  • The initial pediatric dose of midazolam for sedation/anxiolysis/amnesia is age, procedure, and route dependent (see DOSAGE AND ADMINISTRATION for complete dosing information). (nih.gov)
  • The effects of midazolam on the CNS are dependent on the dose administered, the route of administration, and the presence or absence of other medications. (nih.gov)
  • the time of onset is affected by total dose administered and the concurrent administration of narcotic premedication. (nih.gov)
  • Under the acidic conditions required to solubilize midazolam in the product, midazolam is present as an equilibrium mixture (shown below) of the closed ring form shown above and an open-ring structure formed by the acid-catalyzed ring opening of the 4,5-double bond of the diazepine ring. (nih.gov)
  • In pediatric patients, up to 85% had no recall of pictures shown after receiving intramuscular midazolam compared with 5% of the placebo controls. (nih.gov)